ten23 health® and BD Partner to Advance Portable Injection Solutions

ten23 health® has announced a strategic manufacturing partnership with BD to support the commercialization of the BD Libertas™ Wearable Injector, a ready-to-use platform designed for the subcutaneous delivery of high-volume biologic drugs.

This collaboration responds to the growing demand for self-administered therapies by offering biopharmaceutical companies a fully integrated solution, combining BD’s injector technology with ten23 health’s expertise in process development, aseptic filling, assembly, and quality control. The platform supports both 5 mL and 10 mL glass cartridges, enabling greater flexibility and ease of use for patients.

A key element of the partnership is ten23 health’s recently launched Line 0, which allows pharmaceutical companies to test cartridge compatibility, conduct stability studies, and optimize filling and stoppering processes under representative conditions—without the time and cost of full GMP production. This approach accelerates development and reduces risks on the path to scale-up.

By combining BD’s device platform with ten23 health’s integrated CDMO services, the partners aim to strengthen the supply chain for high-dose subcutaneous therapies and support smoother regulatory pathways.

“This collaboration reflects our commitment to improving patient treatment outcomes and delivering innovative, reliable solutions for complex drug delivery programs,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health.

Together, BD and ten23 health are helping shape the future of portable, patient-friendly injection technologies.

➡️ Source: Press Release | 📸 ©ten23 health®